Premium
Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection
Author(s) -
Bunchorntavakul C.,
Reddy K. R.
Publication year - 2015
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.13264
Subject(s) - daclatasvir , ns5a , medicine , sofosbuvir , hepatitis c virus , virology , hepatitis c , protease inhibitor (pharmacology) , pharmacology , hepacivirus , virus , viral load , ribavirin , antiretroviral therapy
Summary Background The treatment of hepatitis C virus ( HCV ) has evolved dramatically after the introduction of direct acting anti‐virals. NS 5A protein plays an important role in HCV replication and is an attractive target for drug development. Aim To review clinical studies on the efficacy and safety of direct‐acting anti‐virals regimens containing daclastavir, an NS 5A inhibitor, in the treatment of chronic hepatitis C. Methods A Medline search was undertaken to identify relevant literature using search terms including ‘daclatasvir’, ‘ HCV treatment’ and ‘ NS 5A inhibitors’. Furthermore, we scanned abstracts presented at the recent international meetings in liver disease, viral hepatitis and infectious disease, as well as the reference lists of the review articles to identify publications not retrieved by electronic searches. Results Daclatasvir is the first‐in‐class HCV NS 5A inhibitor that has been demonstrated in Phase I‐ III trials to have a potent anti‐viral effect and clinical efficacy across multiple HCV genotypes ( GT ). Daclastavir is generally safe and well tolerated, with a low barrier to resistance and low potential for drug–drug interaction. When Daclastavir is added to PEG ‐ IFN / RBV platform, sustained virological response ( SVR ) rates are increased significantly compared with PEG ‐ IFN / RBV alone. The all‐oral combination of Daclastavir /asunaprevir (ASV; protease inhibitor) has high SVR rates against GT 1b, but less activity against GT 1a. Dual combination of Daclastavir /Sofosbuvir (SOF; nucleotide polymerase inhibitor) and triple combination of Daclastavir /ASV/beclabuvir (BCV; non‐nucleoside polymerase inhibitor) have demonstrated >90% SVR rates in both treatment naïve and treatment‐experienced patients with GT 1. Furthermore, Daclastavir /SOF combination has also demonstrated up to 90% SVR rates in patients with GT 3, and in those with human immunodeficiency virus coinfection, cirrhosis and post‐transplant HCV recurrence with any GT . Daclastavir /ASV/BCV has primarily demonstrated near 100% SVR rates in patients with GT 4. Conclusion Daclastavir ‐containing regimens, with or without PEG ‐ IFN , have shown promising results in clinical trials, and present an excellent treatment option for those with chronic HCV and for multiple genotypes.